Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04374136 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
A Phase 3 study, sponsored by Alector.
- Terminated
- Registry status
- Phase 3
- Development phase
- 119
- Enrollment target
NCT04374136 is a Phase 3 study that was terminated before completion, run by Alector. The registered enrollment target is 119 participants.
The verdict
NCT04374136, a Phase 3 study, was terminated before completion, sponsored by Alector.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 119 participants
- Enrollment target
Study Summary
A phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene.
Interventions
- DRUG Placebo
- DRUG AL001
- DRUG Open label - AL001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2020-07-23 |
| Est. Completion | 2026-01-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04374136
The ClinicalTrials.gov registry entry for NCT04374136 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alector, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04374136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04374136 about?
NCT04374136 is a clinical study titled "A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)". A phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene.
What is the current status of trial NCT04374136?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 119 participants. The study started on 2020-07-23. Estimated completion is 2026-01-06.
What interventions are being tested in trial NCT04374136?
The interventions under investigation include: Placebo (DRUG), AL001 (DRUG), Open label - AL001 (DRUG).
Who is sponsoring clinical trial NCT04374136?
This trial is sponsored by Alector, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.